India to Join PIC/S to Safeguard Drug Exports
India is considering joining the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme to safeguard its drug exports.
Singapore: India is mulling over joining a global forum that currently has 43 drug importing countries to ensure safety of drug exports. The forum, officially titled ‘Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme' (PIC/S) has the US and the European Union among its key members.
As per the agreement of this forum, drug regulators of member countries ensure compliance with standards rather than individual manufacturers. The looming fear of India's drug exports suffering in the medium to long term is the reason the country is considering this. "It is going to impact our export growth as more and more countries are now looking for PIC/S compliance. India should join the league at the earliest," said Mr PV Appaji, director general, Pharmaceuticals Export Promotion Council (Pharmaexcil), India.
Further, the country's Commerce Ministry recently initiated a discussion with officials of the Drugs Controller General of India (DCGI) and the health ministry to examine the likely impact of joining the forum.
"As there is the requirement that the whole pharma industry, including non-exporters, be compliant with the standards, the issue needs to studied more carefully," Mr Sudhanshu Pandey, joint secretary, ministry of commerce, opined.
India currently has the highest number of US FDA-approved manufacturing facilities in the world, apart from the US. This is the main reason the country's pharma industry fears losing drug exports to other emerging generic producing nations. India's pharma industry exports grew to $14.5 billion during 2012–2013, up from $13.2 billion the previous year.
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance